Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks hidden risks of hepatitis b drugs in vulnerable patients

NCT ID NCT07529171

Knowledge-focused Sponsor: Yaşar Bayındır, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study follows 490 adults with a past hepatitis B infection who need immune-suppressing treatments. Researchers will monitor bone, kidney, and metabolic health over 4 years to understand the long-term side effects of antiviral drugs. The goal is to create better safety guidelines for these patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 490 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The REANT Cohort is designed as a nationwide, multicenter study conducted across 14 specialized centers in Türkiye. These centers have been strategically selected to reflect a broad geographical and demographic diversity, ensuring a robust representation of the patient population receiving HBV prophylaxis. Participating Provinces: The study will be carried out simultaneously in the following 13 provinces (with 14 participating clinical sites): Ankara, Sivas, İstanbul, Kocaeli, İzmir, Antalya, Adana, Gaziantep, Şanlıurfa, Diyarbakır, Samsun, Rize, Düzce Sample Size Projection:

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older * Positive for Anti-HBc IgG * Must be candidate for immunosuppressive therapy. Exclusion Criteria: * Voluntary Withdrawal * Failure to attend follow-up visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HBV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HBV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Akdeniz University, Faculty of Medicine, Department of Infectious Diseases and Clinical Mİcrobiology

    RECRUITING

    Antalya, Turkey (Türkiye)

  • Ankara Gazi University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Ankara, Turkey (Türkiye)

  • Bilkent City Hospital Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Ankara, Turkey (Türkiye)

  • Bolu Düzce University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Düzce, Turkey (Türkiye)

  • Cukurova University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Adana, Turkey (Türkiye)

  • Dicle University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Diyarbakır, Turkey (Türkiye)

  • Diyarbakir, Memorial Hospital Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Diyarbakır, Turkey (Türkiye)

  • Ege University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Izmir, Turkey (Türkiye)

  • Gaziantep University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Gaziantep, Turkey (Türkiye)

  • Istanbul Haydarpaşa Numune Training and Research Hospital

    RECRUITING

    Istanbul, Turkey (Türkiye)

  • Istanbul Sancaktepe Martyr Prof. Dr. İlhan Varank Training and Research Hospital

    RECRUITING

    Istanbul, Turkey (Türkiye)

  • Kocaeli University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Kocaeli, Turkey (Türkiye)

  • Rize Recep Tayyip Erdogan University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Rize, Turkey (Türkiye)

  • Samsun Ondokuz Mayıs University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Samsun, Turkey (Türkiye)

  • Sivas Cumhuriyet University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Sivas, Turkey (Türkiye)

  • Şanlıurfa Harran University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology

    RECRUITING

    Sanliurfa, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.